RtcB, a novel RNA ligase, can catalyze tRNA splicing and HAC1 mRNA splicing in vivo

Naoko Tanaka, Birthe Meineke, and Stewart Shuman*

From the Molecular Biology Program, Sloan-Kettering Institute, New York, NY 10065 USA

Corresponding author: s-shuman@ski.mskcc.org

Running title: RtcB performs tRNA splicing and HAC1 mRNA splicing

RtcB enzymes are novel RNA ligases that join 2',3'-cyclic phosphate and 5'-OH ends. The phylogenetic distribution of RtcB points to its candidacy as a tRNA splicing/repair enzyme. Here we show that Escherichia coli RtcB is competent and sufficient for tRNA splicing in vivo, by virtue of its ability to complement growth of yeast cells that lack the endogenous “healing/sealing-type” tRNA ligase Trl1. RtcB also protects yeast trl1Δ cells against a fungal ribotoxin that incises the anticodon loop of cellular tRNAs. Moreover, RtcB can replace Trl1 as the catalyst of HAC1 mRNA splicing during the unfolded protein response. Thus, RtcB is a bona fide RNA repair enzyme with broad physiological actions. Biochemical analysis of RtcB highlights the uniqueness of its active site and catalytic mechanism. Our findings draw attention to tRNA ligase as a promising drug target.

Escherichia coli RtcB exemplifies a new family of RNA ligases that directly seal 2',3'-cyclic phosphate and 5'-OH ends (1-3). Direct ligation is thought to be the main pathway of tRNA splicing in animals and archaea (4-6). By contrast, yeast and plants rely on a different mechanism of tRNA splicing, in which the broken 3' and 5' ends are healed (converted to a 3'-OH/2'PO4 and 5'-PO4, respectively) and then sealed by a classical ATP-dependent RNA ligase (7) (Fig. 1). RNA ligases of the RtcB family are present in metazoa and protozoa, but not in fungi and plants. RtcB homologs purified from archaeal and mammalian cells can seal broken tRNA halves and are thereby imputed to be the catalysts of archaeal and mammalian tRNA splicing (2,3). However, this scenario is complicated by the existence of a yeast/plant-like tRNA splicing pathway in mammalian cells (8-12) and of analogous yeast-like RNA repair enzymes in many archaeal taxa (13-16). Definitive genetic evidence concerning the healing-sealing pathway in animals is equivocal. Genetic ablation of a murine homolog of a yeast-like pathway component Tpt1 (the enzyme that removes the 2'-phosphate at the splice junction; Fig. 1) has no discernible phenotype (17), suggesting that the mammalian yeast-like pathway is either functionally redundant with direct ligation or is non-contributory to mammalian tRNA splicing. By contrast, siRNA-directed depletion of the mammalian RNA 5'-kinase (an ortholog of the kinase domain of yeast/plant tRNA ligase) elicited a defect in tRNA splicing in vitro (10). However, siRNA-directed depletion of mammalian RtcB was also reported to inhibit ligation of tRNA halves in cell extracts and to delay tRNA splicing in living cells (3). These findings leave unresolved the following key issues: (i) whether RtcB can suffice for tRNA splicing as the only source of tRNA ligase activity in a eukaryal cell; and (ii) whether RtcB can perform other RNA repair functions in vivo. Here we address these questions by using budding yeast as a surrogate genetic model for tRNA splicing and RNA repair by heterologous enzymes (7).

EXPERIMENTAL PROCEDURES

Expression Plasmids. The bacterial plasmid pET28b-His10Smt3-RtcB encodes wild-type E. coli RtcB fused to an N-terminal His10Smt3 tag (1). Missense mutations were introduced into the RtcB ORF by two-stage overlap extension PCR. The RtcB inserts were sequenced to confirm the desired mutations and exclude the acquisition of unwanted coding changes. The wild-type and mutated RtcB ORFs were excised from their respective pET plasmids and inserted into the yeast vector pRS423 (2µ HIS3) wherein RtcB expression is under the control of the yeast TPI1 promoter. The yeast p(CEN LEU2 gal2PaT) plasmid for galactose-inducible expression of intracellular Pichia acaciae toxin (PaT) lacking the N-terminal 12-aa signal peptide was constructed by excising an NdeI/Sall fragment containing the PaT ORF from plasmid...
pPACBX (18) (a gift of Roland Klassen and Friedhelm Meinhardt) and inserting it into pRS415 (CEN LEU2) between GAL1 promoter and terminator elements.

**RtcB Purification.** The wild-type and mutant pET28b-His<sub>10</sub>Smt3-RtcB plasmids were transformed into *E. coli* BL21-CodonPlus(DE3). Induction of RtcB expression, preparation of soluble lysates, recovery of the His<sub>10</sub>Smt3-RtcB proteins by Ni-agarose chromatography, excision of the tags by treatment with the Smt3-specific protease Ulp1, and separation of the tag-free RtcB proteins from His<sub>10</sub>Smt3 by a second round of Ni-agarose chromatography were performed as described (1). Protein concentrations were determined by using the BioRad dye reagent with BSA as the standard. The polypeptide compositions of the RtcB preparations were analyzed by SDS-PAGE (Figs. S1 and S2).

**RNA repair substrates.** A synthetic RNA oligonucleotide R30 containing the anticondomer stem-loop of yeast tRNA<sub>Glu(UUC)</sub> was 5′-32P-labeled by reaction with T4 Pnkp and [γ-32P]ATP. R30 was then cleaved 3′ of the wobble uridine by reaction with *K. lactis* γ-toxin (1). The 32P-labeled R19>p strand with a 2′,3′ cyclic phosphate end (5′-pUGGCUCCGAUAUCACGCUU>p) was purified by preparative PAGE. Oligonucleotide HOUR20 (5′-pUGGCUCCGAUAUCACGCUU>p) was purified using a synthetic R19 OH oligonucleotide with a 3′-OH end at the break site (Fig. 5) were formed by annealing the RNA requirements for the RtcB ligation single strand at an R20:R19 ratio of 10:1. To test an excess of cold pR20 strand. The pRNA strand was employed to form a broken tRNA-like stem loop (Fig. 4) by mixture with the 5′-32P-labeled R19 single strand at an R20:R19 ratio of 10:1. To test the RNA requirements for the RtcB ligation reaction, the 32P-labeled R19>p strand was also annealed to a synonymous deoxyuridine-containing HOUD20 oligonucleotide to form a broken RNA:DNA hybrid stem loop (Fig. 5).

Alternative stem-loop RNA repair substrates with a 3′-OH end at the break site (Fig. 5) were prepared using a synthetic R19OH oligonucleotide that had been 5′-32P-labeled and then purified by PAGE. The labeled R19OH oligonucleotide was annealed to a 10-fold excess of unlabeled D20 and R20 strands.

RNA repair substrates with a 5′-PO4 at the break site (Fig. 5) were formed by annealing radiolabeled R19>p or R19OH strands to a 10-fold excess of cold pR20 strand. The pRNA strand was generated by enzymatic phosphorylation of HOUS20 using T4 Pnkp and cold ATP, then purified by PAGE.

**RESULTS AND DISCUSSION**

Here we interrogated the tRNA repair function of *E. coli* RtcB in *in vivo* by complementation of a lethal deletion of the *TRL1* gene encoding the tRNA ligase of *Saccharomyces cerevisiae* (7). Yeast Trt1 is a trifunctional tRNA repair enzyme (with 5′-OH kinase, 2′,3′ cyclic phosphodiesterase, and ATP-dependent RNA ligase activities) that heals and seals the broken tRNA halves with 2′,3′ cyclic phosphate and 5′-OH ends generated by incision of pre-tRNAs at the exon-intron junctions (Fig. 1). *E. coli* RtcB is a monofunctional ligase that directly joins 2′,3′ cyclic phosphate and 5′-OH ends (1). (Fig. 1). We expressed the 408-aa *E. coli* RtcB protein in *S. cerevisiae* under the control of a constitutive promoter on a 2µ plasmid and demonstrated by plasmid shuffle that RtcB could indeed sustain growth of a trl1∆ strain (Fig. 1). These results prove that RtcB is able and sufficient to perform the essential repair steps of eukaryal tRNA splicing *in vivo*.

The discovery that the healing and sealing activities of yeast Trt1 are also responsible for unconventional splicing of the *HAC1* mRNA in the yeast unfolded protein response (UPR) pathway (19,20) extended the RNA repair paradigm to mRNA metabolism. Endoplasmic reticulum stress induces the Ire1 endonuclease to cleave *HAC1* mRNA at two sites, which liberates a 252-nucleotide intron (Fig. 2) and leaves 2′,3′ cyclic phosphate and 5′-OH termini on the proximal and distal exons, respectively. Healing and sealing of the exons by Trt1 creates a new open reading frame encoding an active Hac1 transcription factor. The mammalian UPR entails stress-induced Ire1 cleavage and unconventional splicing of the *XBP1* mRNA (21), but the enzyme responsible for sealing the broken *XBP1* transcript is not known. Here we tested the capacity of RtcB to execute unconventional mRNA splicing during the yeast UPR. Yeast *TRL1* cells exposed to tunicamycin shifted their *HAC1* mRNA profile, as assayed by RT-PCR with primers flanking the intron, whereby the intron-containing long form was replaced by a spliced short form (Fig. 2). Sequencing of the isolated RT-PCR products confirmed their identity as unspliced and spliced *HAC1* cDNAs, respectively. Yeast *trl1∆* cells reliant on RtcB as their source of tRNA ligase were proficient in generating the spliced *HAC1* RNA in the presence of tunicamycin (Fig. 2), signifying that RtcB is
competent for mRNA splicing in the eukaryal UPR. Sequencing of the RT-PCR product verified that the Ire1 endonuclease cleavage sites were ligated faithfully.

Another manifestation of tRNA repair is the capacity to protect cells from the cytotoxicity inflicted by tRNA-specific ribotoxins that incise the anticodon loop by a transesterification mechanism that leaves 2',3' cyclic phosphate and 5'-OH termini at the broken tRNA ends (22,23). *Pichia acaciae* toxin (PaT) is a secreted fungal defense molecule that penetrates *S. cerevisiae* cells and, upon accessing the cytoplasm, breaks the anticodon molecule that penetrates *S. cerevisiae* cells and, upon accessing the cytoplasm, breaks the anticodon loop by a transesterification mechanism inflicted by tRNA-specific ribotoxins that incise the anticodon loop of tRNA\(^{\text{Glu(UUC)}}\). Consequent depletion of the tRNA\(^{\text{Glu(UUC)}}\) pool arrests yeast growth (18). Galactose-induced expression of an intracellular form of PaT recapitulates its toxicity (18). The salient finding here was that replacing yeast Trl1 with RtcB as the source of tRNA ligase protected *S. cerevisiae* from PaT-mediated growth inhibition (Fig. 3). Taken together, these experiments establish that RtcB is a tRNA/mRNA repair enzyme with broad physiological actions.

The RtcB sealing reaction is postulated to entail nucleophilic attack by the O5' nucleophile on the cyclic phosphate, with expulsion of the ribose O2'. Our initial findings that RtcB is manganese-dependent (1) indicated that sealing is not merely reversal of the metal-independent cleavage transesterification mechanism used by tRNA splicing endoribonuclease and tRNA-damaging anticodon nucleases. Manganese might promote RtcB catalysis by coordinating the O5' nucleophile to lower its pK\(_a\) and/or engaging the cyclic-phosphate oxygens to stabilize the transition state. The mechanistic novelty of RtcB is underscored by the crystal structure of the RtcB homolog from *Pyrococcus horikoshii* (24) (Fig. 4). RtcB has a distinctive tertiary structure with no similarity to any known ligases or phosphotransferases. RtcB has a deep and wide hydrophilic pocket lined by conserved histidines and a cysteine, suggestive of a metal-binding site that, being dominated by “soft” metal contacts to histidine nitrogens and cysteine sulfur, could account for the fact that *E. coli* RtcB requires manganese and is virtually inactive with magnesium (1). A water coordinated by the equivalents of *E. coli* RtcB side chains Asp75, Cys78, Asn167 and His168 is a potential mimic of the enzyme-bound metal (Fig. 4). Flanking the putative metal site in RtcB are two sulfate anions (potential mimetics of RNA phosphates) coordinated by basic amino acid side chains equivalent to *E. coli* RtcB residues Lys298, His168 and Arg189 (Fig. 4).

Here we used the *Pyrococcus* RtcB structure to guide a mutational analysis of 11 conserved residues in *E. coli* RtcB that we thought might comprise an active site (Fig. 4). Recombinant RtcB and RtcB-Ala proteins were produced in bacteria purified from soluble lysates (Fig. S1). The proteins were tested for ligase activity with a broken tRNA-like substrate (1) modeled on the anticodon stem-loop of yeast tRNA\(^{\text{Glu(UUC)}}\) (Fig. 4). Whereas RtcB and mutant H280A sealed ~80% of the stem-loop substrate in vitro, mutants D75A, C78A, H168A, R189A, H337A, and R341A were virtually inert, with <1% ligation (Fig. 4). Mutants N167A, H185A, R189A and K298A were severely impaired (sealing 3%, 5%, and 3% of the substrate, respectively) and R345A was modestly impaired (24% sealing). Each of the RtcB-Ala mutants was tested for *trl1Δ* complementation in yeast; only H280A was functional (Fig. 4).

Structure-activity relations at seven of the RtcB amino acids defined as essential by the alanine scan were probed by introducing conservative substitutions (Fig. S2). Replacing Asp75 by either asparagine or glutamate inactivated RtcB, attesting to the requirement for a carboxylate at this position and the steric constraints on the main-chain to carboxylate distance (Fig. S2). Changing Cys78 to serine abolished ligase activity, signifying that the S\(_7\) atom is critical. His168 and His337 were replaced by glutamine and asparagine; the H168N, H168Q, H337N and H337Q mutants were catalytically inactive (Fig. S2). The mutational effects are consistent with roles for Asp75, Cys78, His168, Asn167, His185 and His337 in metal binding and/or RNA transesterification. Whereas replacing the sulfate-binding Lys298 with glutamine phenocopied K298A, the arginine substitution restored ligation to one-fourth of the wild-type RtcB (Fig. S2), highlighting positive charge as the key property of this residue. By contrast, neither Arg189 nor Arg341 could be functionally substituted by lysine or glutamine, implying that the multivalent ionic and hydrogen bonding contacts of these arginines seen in the RtcB crystal structure (Fig. 4) are indeed pertinent to enzyme activity, either via binding to the RNA phosphates (a putative function of Arg189) or in stabilizing the active site conformation (a likely role...
of Arg341). None of the conservative mutants complemented trl1Δ (not shown).

Further insights to the substrate specificity of RtcB were gained by varying the 3’ and 5’ termini of the broken stem-loop substrate and testing the capacity of a 5’-OH DNA strand to serve as the nucleophile for the sealing reaction. A 5’ 32P-labeled 19-mer RNA with either a 2’,3’ cyclic phosphate end (R19>p) or a 3’-OH end (R19,OH) was annealed to an unlabeled 20-mer strand composed of all-ribonucleotides (R20) or all deoxynucleotides (D20) to form the broken stem-loops depicted in Fig. 5. The unlabeled 20-mer strands had either a 5’-OH terminus (HOR20 or HOD20) or a 5’-PO4 terminus (pR20). The results of the ligation assays established that: (i) 2’,3’ cyclic phosphate and 5’-OH ends are the only suitable reactants for E. coli RtcB among the combinations tested and (ii) RtcB is adept at joining the R19>p “donor” strand to either RNA or DNA “acceptor” strands so long as they have a 5’-OH end. The versatility of RtcB with respect to the 5’-OH acceptor suggests practical applications for this enzyme in tagging and/or cloning mature RNAs or RNA processing intermediates that have 2’,3’ cyclic phosphate ends.

In summary, we have provided convincing genetic and biochemical evidence that RtcB can serve as a genuine tRNA splicing/repair enzyme in a eukaryal cell. Our findings here and previously (7) attest to the portability of viral, fungal, plant, and bacterial tRNA repair systems. The salient theme is that sealing by any of several distinct enzymatic/chemical pathways, suffices for tRNA splicing and unconventional mRNA splicing in vivo. The candidacy of mammalian RtcB homolog an agent of tRNA splicing by direct ligation is supported by our genetic results. However, the jury is still out as to whether RtcB is functionally redundant with a mammalian tRNA repair pathway via sequential end-healing and end-sealing steps (8,10).

Our findings also fortify the case for the Trl1-associated ligase as a promising antifungal drug target, for the following reasons: (i) Trl1 is present in all fungal proteomes; (ii) ligase-inactivating mutations in the active site of Trl1 are lethal in vivo (25,26); and (iii) mammalian taxa encode no homolog of the Trl1 ligase domain. Thus, any ATP-dependent ligase involved in the putative mammalian healing-sealing pathway (8) must either belong to a different enzyme family, or have diverged so far from a fungal-type ancestor as to be unrecognizable. In either event, one predicts that a mechanism-based inhibitor of the Trl1 ligase should selectively block fungal growth without affecting mammalian cells. By the same token, an antagonist of RtcB might be useful in transiently impeding the UPR for therapeutic benefit in human diseases involving ER stress (21). The availability of isogenic yeast strains with orthogonal tRNA splicing systems should enable differential cell-based screening for bioactive molecules that selectively inhibit growth by targeting Trl1 versus RtcB and vice versa.

Acknowledgements. This research was supported by NIH grant GM46330.
REFERENCES


Figure Legends

Figure 1. **RtcB can perform eukaryal tRNA splicing in vivo.** The two pathways of tRNA splicing – via end-healing and end-sealing in yeast and plants (catalyzed in *S. cerevisiae* by the tRNA ligase Trl1) or via direct ligation in animals and archaea (where RtcB is a putative catalyst) – are shown. The capacity of *E. coli* RtcB to complement an *S. cerevisiae* trl1Δ mutant was assayed by plasmid shuffle. Yeast *trl1Δ* p(*CEN URA3 TRL1*) cells transformed with a 2µ *HIS3* plasmid (vector control) or 2µ *HIS3* plasmids encoding Trl1 or RtcB under the control of a yeast TPII promoter were selected for histidine prototrophy and then streaked on agar medium containing 0.75 mg/ml 5-fluoroorotic acid (a drug that selects against the *URA3 TRL1* plasmid). The plate was photographed after 3 d at 30°C.

Figure 2. **RtcB can perform HAC1 mRNA splicing in the unfolded protein response.** The unprocessed yeast *HAC1* open reading frame, containing a 252-nucleotide intron, is depicted at the bottom. To gauge *HAC1* mRNA splicing, cultures (10 ml) of *S. cerevisiae trl1Δ* p(2µ *HIS3 TRL1*) and *trl1Δ* p(2µ *HIS3 RtcB*)...
cells were grown at 30°C in YPD media until the $A_{600}$ reached 0.6. The cultures were split into 5 ml aliquots, one of which was adjusted to 1.5 µg/ml tunicamycin to induce ER stress. One hour later, the cells were harvested by centrifugation. Total RNA was isolated by using a yeast RNA purification kit (Epicentre Biotechnologies). $HAC1$ transcripts were detected by RT-PCR using primers flanking the intron. The cDNAs were synthesized by using the Superscript III System (Invitrogen) with 1.0 µg of total RNA as template and 0.1 µM of $HAC1$-specific antisense primer (5'-dCATGAAGTGATGAAGAAATCATTCAATT; complementary to nucleotides 940–968). The cDNAs were amplified by 22 cycles of PCR with Herculase (Stratagene) using the antisense primer and a sense-strand primer (5'-dCCAAGGAAAAAGCAGCAGACAAAAGAGG; corresponding to nucleotides 82-109). The RT-PCR products were analyzed by 1.4% agarose gel electrophoresis. A negative image of the ethidium bromide-stained gel is shown. The positions and sizes (bp) of marker dsDNAs are indicated at left. The predicted sizes of the unspliced and spliced $HAC1$ RT-PCR products are 886 bp and 634 bp, respectively.

Figure 3. RtcB protects cells from cytotoxic tRNA damage. (Top) Schematic depiction of yeast cells harboring $GAL1$ PaT plasmid with 5-FOA selection in the presence of glucose or galactose as the carbon source. The right-most cell expresses RtcB in lieu of Trl1. (Bottom) $S. cerevisiae$ TRL1 and trl1∆ RtcB cells were transformed with either a CEN LEU2 GAL1 PaT plasmid or with an empty CEN LEU2 vector. Cultures derived from single Leu + colonies were grown in SD-Leu medium at 37°C. After adjustment to $A_{600}$ of 0.1, aliquots (3 µl) of serial 5-fold dilutions of the cells were spotted on –Leu agar plates containing either 2% glucose or 2% galactose. The plates were photographed after incubation for 3 d (glucose) or 4 d (galactose) at 37°C.

Figure 4. Structure-guided mapping of the RtcB active site. (Top) Stereo view of the putative active site pocket of Pyrococcus horikoshii RtcB (from pdb 1UC2). The conserved amino acid residues that were subjected to alanine scanning in E. coli RtcB are shown as stick models with beige carbons and are labeled according to their E. coli RtcB equivalents. Two sulfate anions bound to RtcB are rendered as stick models. A water molecule that could plausibly mimic the metal cofactor is depicted as a red sphere. Ionic and hydrogen-bonding interactions are denoted by dashed lines. (Bottom) RNA ligase reaction mixtures (10 µl) containing 50 mM Tris-HCl (pH 8.0), 2 mM MnCl$_2$, 100 µM GTP, 100 nM of 5'-32P-labeled broken RNA stem-loop substrate (depicted at right), and 2 µM wild-type RtcB or RtcB-Ala mutants (see Fig. S1) were incubated for 30 min at 37°C. The reactions were quenched by adding 10 µl of 40 mM EDTA/95% formamide, and the products were analyzed by electrophoresis through a 20% polyacrylamide gel containing 7 M urea in 45 mM Tris-borate, 1.25 mM EDTA. The extents of conversion of the radiolabeled 19-mer substrate strand into sealed 39-mer product (% ligation) were quantified by scanning the gel with a Fuji Film BAS-2500 imager. Each datum in the bar graph is the average of three separate ligation experiments ±SEM. The RtcB-Ala ORFs were cloned into yeast 2 µ plasmids under the control of the TPI1 promoter and tested for trl1∆ complementation as described in Fig. 1. The results are summarized below the graph.
Figure 1
Figure 2
Figure 3

- Glucose
- Galactose
- Galactose

$TRL1$

$trl1Δ \text{ RtcB}$

vector
vector

PaT
PaT

glucose
galactose
Figure 4
Figure 5
RtcB, a novel RNA ligase, can catalyze tRNA splicing and HAC1 mRNA splicing in vivo
Naoko Tanaka, Birthe Meineke and Stewart Shuman
J. Biol. Chem. published online July 11, 2011

Access the most updated version of this article at doi: 10.1074/jbc.C111.274597

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC’s e-mail alerts

Supplemental material:
http://www.jbc.org/content/suppl/2011/07/11/C111.274597.DC1

This article cites 0 references, 0 of which can be accessed free at
http://www.jbc.org/content/early/2011/07/11/jbc.C111.274597.full.html#ref-list-1